Pegfilgrastim on febrile neutropenia in pediatric and adolescent cancer patients: a systematic review and meta-analysis

References

• Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American society of clinical oncology and infectious diseases society of America clinical practice guideline update. J Clin Oncol. 2018;36(14):1443–1453.
   PubMed Web of Science ®Google Scholar
• Wang XJ, Chan A. Optimizing symptoms and management of febrile neutropenia among cancer patients: current status and future directions. Curr Oncol Rep. 2017;19(3):20.
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2011;52(4):e56–e93.
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T, Robinson P, Fisher B, et al. Guideline for the management of fever and neutropenia in children With cancer and hematopoietic stem-cell transplantation recipients: 2017 update. J Clin Oncol. 2017;35(18):2082–2094.
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Akova M, Herbrecht R, et al. ESCMID* guideline for the diagnosis and management of candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect. 2012;18(Suppl 7):53–67.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2015;33(28):3199–3212.
   PubMed Web of Science ®Google Scholar
• Chu S, McCormick TS, Lazarus HM, et al. Invasive fungal disease and the immunocompromised host including allogeneic hematopoietic cell transplant recipients: improved understanding and new strategic approach with sargramostim. Clin Immunol. 2021;228:108731.
   PubMed Web of Science ®Google Scholar
• Scriven JE, Tenforde MW, Levitz SM, et al. Modulating host immune responses to fight invasive fungal infections. Curr Opin Microbiol. 2017;40:95–103.
   PubMed Web of Science ®Google Scholar
• Rofail P, Tadros M, Ywakim R, et al. Pegfilgrastim: a review of the pharmacoeconomics for chemotherapy-induced neutropenia. Expert Rev Pharmacoecon Outcomes Res. 2012;12(6):699–709.
   PubMed Web of Science ®Google Scholar
• Renwick W, Pettengell R, Green M. Use of filgrastim and pegfilgrastim to support delivery of chemotherapy: twenty years of clinical experience. Bio Drugs. 2009;23(3):175–186.
   Google Scholar
• Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47(1):8–32.
   PubMed Web of Science ®Google Scholar
• Leonard RC, Mansi JL, Keerie C, et al. A randomised trial of secondary prophylaxis using granulocyte colony-stimulating factor (‘SPROG’ trial) for maintaining dose intensity of standard adjuvant chemotherapy for breast cancer by the Anglo-Celtic Cooperative Group and NCRN. Ann Oncol. 2015;26(12):2437–2441.
   PubMed Web of Science ®Google Scholar
• Kelly S, Wheatley D. Prevention of febrile neutropenia: use of granulocyte colony-stimulating factors. Br J Cancer. 2009;101(Suppl 1):S6–10.
   PubMedGoogle Scholar
• Barnes G, Pathak A, Schwartzberg L. G-CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF use. Cancer Med. 2014;3(6):1477–1484.
   PubMed Web of Science ®Google Scholar
• Link H, Nietsch J, Kerkmann M, et al. Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy–a representative sample survey in Germany. Support Care Cancer. 2016;24(1):367–376.
   PubMed Web of Science ®Google Scholar
• Weycker D, Hackett J, Edelsberg JS, et al. Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother. 2006;40(3):402–407.
   PubMed Web of Science ®Google Scholar
• Neulasta AL. Summary of product characteristics 2015 [Available from: https://www.ema.europa.eu/en/documents/product-information/neulasta-epar-product-information_en.pdf.
   Google Scholar
• Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol. 2005;23(6):1178–1184.
   PubMed Web of Science ®Google Scholar
• Mey UJ, Maier A, Schmidt-Wolf IG, et al. Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma. Support Care Cancer. 2007;15(7):877–884.
   PubMed Web of Science ®Google Scholar
• Ozer H, Mirtsching B, Rader M, et al. Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use. Oncologist. 2007;12(4):484–494.
   PubMed Web of Science ®Google Scholar
• Pro B, Fayad L, McLaughlin P, et al. Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma. Leuk Lymphoma. 2006;47(3):481–485.
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen L, Liu F, et al. Efficacy and tolerability of granulocyte colony-stimulating factors in cancer patients after chemotherapy: A systematic review and Bayesian network meta-analysis. Sci Rep. 2019;9(1):15374.
   PubMedGoogle Scholar
• Bond TC, Szabo E, Gabriel S, et al. Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events. J Oncol Pharm Pract. 2018;24(6):412–423.
   PubMed Web of Science ®Google Scholar
• Cornes P, Gascon P, Chan S, et al. Systematic review and meta-analysis of short- versus long-acting granulocyte colony-stimulating factors for reduction of chemotherapy-induced febrile neutropenia. Adv Ther. 2018;35(11):1816–1829.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Reiner M, Morrow PK, et al. The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppressive chemotherapy. Ann Oncol. 2015;26(7):1452–1458.
   PubMed Web of Science ®Google Scholar
• Link H. Current state and future opportunities in granulocyte colony-stimulating factor (G-CSF). Support Care Cancer. 2022;30(9):7067–7077.
   PubMed Web of Science ®Google Scholar
• Selcuk AA. A guide for systematic reviews: PRISMA. Turk Arch Otorhinolaryngol. 2019;57(1):57–58.
   PubMedGoogle Scholar
• Higgins JPT, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions version 6.0 (updated July 2019). London: Cochrane Collaboration; 2019.
   Google Scholar
• Higgins JP, Altman DG, Gotzsche PC, et al. The cochrane collaboration's tool for assessing risk of bias in randomised trials. Br Med J. 2011;343:d5928.
   PubMed Web of Science ®Google Scholar
• Coen D, Cortellaro F, Pasini S, et al. Towards a less invasive approach to the early goal-directed treatment of septic shock in the ED. Am J Emerg Med. 2014;32(6):563–568.
   PubMed Web of Science ®Google Scholar
• Excellence NIfHaC. Appendix 4 Quality of case series form [Available from: https://www.nice.org.uk/guidance/cg3/documents/appendix-4-quality-of-case-series-form2.
   Google Scholar
• Slim K, Nini E, Forestier D, et al. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712–716.
   PubMed Web of Science ®Google Scholar
• Ding H, Hu GL, Zheng XY, et al. The method quality of cross-over studies involved in Cochrane Systematic Reviews. PLoS One. 2015;10(4):e0120519.
   PubMed Web of Science ®Google Scholar
• te Poele EM, Kamps WA, Tamminga RY, et al. Pegfilgrastim in pediatric cancer patients. J Pediatr Hematol Oncol. 2005;27(11):627–629.
   PubMed Web of Science ®Google Scholar
• Wendelin G, Lackner H, Schwinger W, et al. Once-per-cycle pegfilgrastim versus daily filgrastim in pediatric patients with Ewing sarcoma. J Pediatr Hematol Oncol. 2005;27(8):449–451.
   PubMed Web of Science ®Google Scholar
• Yousofian S, Miri-Aliabad G, Kiumarsi A, et al. Effectiveness of filgrastim and polyethylene glycol-filgrastim in the treatment of postchemotherapy neutropenia in children: phase I clinical trial. Indian J Med Paed Oncol. 2019;40(1):101–104.
   Web of Science ®Google Scholar
• Spunt SL, Irving H, Frost J, et al. Phase II, randomized, open-label study of pegfilgrastim-supported VDC/IE chemotherapy in pediatric sarcoma patients. J Clin Oncol. 2010;28(8):1329–1336.
   PubMed Web of Science ®Google Scholar
• Andre N, Kababri ME, Bertrand P, et al. Safety and efficacy of pegfilgrastim in children with cancer receiving myelosuppressive chemotherapy. Anticancer Drugs. 2007;18(3):277–281.
   PubMed Web of Science ®Google Scholar
• Milano-Bausset E, Gaudart J, Rome A, et al. Retrospective comparison of neutropenia in children with Ewing sarcoma treated with chemotherapy and granulocyte colony-stimulating factor (G-CSF) or pegylated G-CSF. Clin Ther. 2009;31(Pt 2):2388–2395.
   PubMedGoogle Scholar
• Borinstein SC, Pollard J, Winter L, et al. Pegfilgrastim for prevention of chemotherapy-associated neutropenia in pediatric patients with solid tumors. Pediatr Blood Cancer. 2009;53(3):375–378.
   PubMed Web of Science ®Google Scholar
• Lopez-Facundo NA, Valois-Escamilla MG, Tejocote-Romero I, et al. Cost-benefit study of febrile neutropenia prophylactic treatment with pegfilgrastim vs. filgrastim in pediatric patients with solid tumors. Gaceta Mexicana dew Oncologia. 2017;16(1):31–35.
   Google Scholar
• Sung L, Nathan PC, Lange B, et al. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials. J Clin Oncol. 2004;22(16):3350–3356.
   PubMed Web of Science ®Google Scholar
• Copley MR, Eaves CJ. Developmental changes in hematopoietic stem cell properties. Exp Mol Med. 2013;45:e55.
   PubMed Web of Science ®Google Scholar
• Fernandez KS, de Alarcon PA. Development of the hematopoietic system and disorders of hematopoiesis that present during infancy and early childhood. Pediatr Clin North Am. 2013;60(6):1273–1289.
   PubMed Web of Science ®Google Scholar
• Akashi M, Shibuya Y, Kusumoto J, et al. Myelosuppression grading of chemotherapies for hematologic malignancies to facilitate communication between medical and dental staff: lessons from two cases experienced odontogenic septicemia. BMC Oral Health. 2013;13:41.
   PubMed Web of Science ®Google Scholar
• Gordon MS. Myelosuppression. Current cancer therapeutics. London: Current Medicine Group; 2001.
   Google Scholar